1. A pharmaceutical combination for use to reduce plasma glucagon levels in patients with type 2 diabetes, said combination comprising (a) desProexendin-4 (1-39) -Lys-NHand / or a pharmaceutically acceptable salt thereof, (b) metformin and / or a pharmaceutically acceptable salt thereof, and (c) sulfonylurea, wherein the subject to be treated has a postprandial plasma glucose concentration 2 hours after a meal of at least 14 mmol / L. 2. The pharmaceutical combination according to claim 1, wherein the subject to be treated has glucose fluctuations of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, or at least 5 mmol / L, and the glucose fluctuation is the difference between the postprandial plasma glucose concentration 2 hours after a meal and the plasma glucose concentration 30 minutes before a meal test. 3. The pharmaceutical combination of claim 1 or 2, wherein the subject to be treated is obese. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg / m. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is an adult subject. The pharmaceutical combination according to claim 1 or 2, wherein the subject being treated has been diagnosed with type 2 diabetes at least 1 year or at least 2 years before starting therapy. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has an HbA value of from about 7 to about 10%. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has a concentration of1. Фармацевтическая комбинация для применения с целью снижения уровня глюкагона в плазме у пациентов с диабетом типа 2, при этом указанная комбинация содержит(a) desProэксендин-4(1-39)-Lys-NHи/или его фармацевтически приемлемую соль,(b) метформин и/или его фармацевтически приемлемую соль, и(с) сульфонилмочевину,при этом субъект, подвергаемый лечению, имеет постпрандиальную
